Articles On Paradigm Biopharmaceuticals (ASX:PAR)

In early afternoon trade the S&P/ASX 200 Index (ASX: XJO) is fighting hard to stay in positive territory. At the time of writing, the benchmark index is up slightly to 5,956.2 points. Four shares that are climbing more than most today...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been a very strong performer on Tuesday. In morning trade the biopharmaceutical company’s shares are up a sizeable 12% to $2.70. Why is the Paradigm share price surging higher?...

The exclusive supply of Pentosan Polysulphate Sodium for 25 years following marketing approval provides a greater level of commercial protection for Paradigm as it progresses towards commercialisation of Zilosul® in Europe.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) updated the market today on its phase III trial and product registration in Europe. The news shot the Paradigm share price 8.3% higher to $2.47 at the time of writing. In comparison, the All Ordin...

Positive feedback has been received from European Medicines Agency after Paradigm’s recent Scientific Advice meeting, a key regulatory milestone which supports and validates the company’s clinical development and commercialisation plans for...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is slightly higher today, up 0.38% at the time of writing to $2.66. This came after the company released its annual report for the year ended 30 June 2020. What were the FY20 resul...

The ASX is littered with small-cap shares all vying to be global leaders in their fields. These innovative start-up companies seek to pursue untapped market opportunities that could one day bring them to stardom like industry giants CSL Li...

Paradigm’s investigation of PPS for MPS seeks to establish whether PPS may be an effective adjunct/combination therapy with current Enzyme Replacement Therapy treatments.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With quart...

On Wednesday I looked at three ASX shares that brokers have given buy ratings to this week. Unfortunately, not all shares are in favour with them right now. Three ASX shares that have just been given sell ratings by brokers are listed belo...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price rallied 9.6% in morning trade before pulling back to a gain of 0.9% at the time of writing. The rise in the Paradigm share price came after the company reported pain reduction in o...

Patients in the Expanded Access Program treated with Paradigm’s Phase 3 Zilosul® product was well tolerated with no serious Adverse Events reported.

It’s been a great day for Australian shares today, with the S&P/ASX 200 Index (ASX: XJO) up by 2.3% at the time of  writing. In particular, the biotech sector and the tech sector have been standout performers. Here we examine 4 ASX bio...

I believe ASX medical shares are among the most defensive on the market. After all, people require medical treatment regardless of the state of the economy. Despite the volatility seen in share markets as a result of COVID-19, the S&P/...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price climbed over 13% today before edging back to a more modest gain of 6% by the market’s close. The Paradigm share price increase came after the healthcare company revealed promising...

The company remains focused on its IND submission to the FDA for the remainder of 2020.

In early afternoon trade the S&P/ASX 200 Index (ASX: XJO) has followed the lead of U.S. markets and is on course to record a very strong gain. At the time of writing the benchmark index is up 1.2% to 6,011.2 points. Four shares that ar...

Bell Financial Group (ASX:BFG) is expecting to book a higher $23.5m first-half profit, but investors didn’t seem overly happy about it with shares dipping 5.2 per cent on Friday morning. The figure is 5 per cent up on the same period last y...

Dr Donna Skerrett has more than 30 years in the pharmaceutical industry and has been the company's chief medical officer since September 2019.

Paradigm is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.

Paradigm Biopharmaceuticals has been added to the S&P/ASX 300 Index while Alkane Resources, De Grey Mining, Legend Mining, Greenland Minerals and Salt Lake Potash are additions to the All Ordinaries index.

The company is preparing for phase-3 trials in both Osteoarthritis (OA) and Mucopolysaccharidosis (MPS).

Healthcare is not the favourite child it was at the start of the COVID-19 pandemic, but one index measuring the sector is still up on the wider market. Biotech Daily’s top 40 index is up 14 per cent over the last month, compared to 4 per ce...

The ASX is home to a small but vibrant and growing biotechnology sector. There are a number of providers that are making significant inroads on a global scale. Here we examine 3 ASX biotech shares that have all seen strong share price rise...

From the bulging file of Nasty Obscure Diseases we present idiopathic intracranial hypertension (IIH), a condition characterised by debilitating chronic daily headaches and in some cases severe vision impairment. It’s a poorly treated condi...

The past fortnight has seen another interesting list of buyers and sellers. Angel Seafood (ASX:AS1) CEO Issac Lee Halman had to sell $195,000 in shares to pay a tax bill. The company said he had no other choice because the majority of his a...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Participating in small cap raises is proving lucrative for investors, with shares in 47 small caps that tapped equity markets in April currently trading higher than the price at which they raised cash. Stockhead counted at least 66 offers i...

The company recently reported a 45% reduction in pain across 34 patients with knee osteoarthritis (OA) using its phase 3 clinical trial product Zilosul.

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

Special Report: Drug developer Dimerix hasn’t been affected by the March market rout and since April has surged. What is behind this push? Shares in drug developer Dimerix (ASX:DXB) have doubled in value in the last six months and the stock...

It’s still a relatively difficult market to raise capital in, particularly at the junior end, but there are some that have convinced investors to part with their hard earned cash. We run through just which small and micro caps successfully...

Paradigm Biopharmaceuticals (ASX: PAR) has completed treatment of its Zilosul injectable pentosan polysulfate (iPPS) drug under the US Food and Drug Administration’s expanded access program, while collaring FDA orphan status for using it in...

Earlier this month, Paradigm reported a 45% mean reduction in pain score across 34 patients with knee osteoarthritis (OA) using Zilosul.

The Paradigm Biopharmaceuticals Limited (ASX: PAR) share price is up 9.03% at the time of writing after the healthcare company reported strong results from its clinical studies. Paradigm’s drug Zilosul reportedly reduced chronic pain in os...

We know that gambling dens aren’t open in these days of social distancing, but metaphorically speaking Paradigm Pharmaceuticals (ASX:PAR) is plonking it all on the black in terms of its “ballsy” pursuit of US approval for its drug for osteo...

The recent market announcements and $35 million capital raise have provided significant clarity to numerous aspects of the company’s development pathway for Zilusol.

The company aims to develop and commercialise its safe and effective treatment for sufferers of osteoarthritis.

Zilosul was successful in reducing knee osteoarthritis pain score by 45%.

Drug company Paradigm Biopharmaceuticals has had Bell Potter line up investors for a $35 million equity raising.

The halt will remain in place until Monday, April 6, or until an announcement is released to the market.

Humanity is against a race with time, as the pandemic coronavirus is accelerating. According to the WHO, the number of confirmed cases across the globe has exceeded 3,81,598, while the number of deaths has surpassed 16,000 (as on 24 March 2...

The S&P/ASX 200 Index (ASX: XJO) has returned to form on Tuesday. In late morning trade the benchmark index is up a decent 2.3% to 4,650.5 points. Four shares that are climbing more than most today are listed below. Here’s why they are...

10 Patients are being treated for knee osteoarthritis using the trademarked injectable pentosan polysulphate sodium drug Zilosul®.

An experimental treatment for knee osteoarthritis developed by Paradigm Biopharmaceuticals (ASX: PAR), Zilosul, has now been dosed in all ten patients under the FDA approved expanded access – otherwise known as compassionate use – program i...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is charging higher on Tuesday morning. At the time of writing the biopharmaceutical company’s shares are up 17% to $1.41. Why is the Paradigm share price charging higher? Investors...

The ASX healthcare sector continues to be one of the top performers on the ASX in terms of share price rises over the past 12 months, despite all the strong market correction. While most Australians are likely familiar with healthcare comp...

Over the last 12 months there have been some outstanding performers on the Australian share market. Some shares have beaten the market with solid gains and others have absolutely smashed it with mouth-watering gains. Here’s why these All O...

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is an Australian biopharmaceutical company, which focuses on repurposing pentosan polysulfate sodium (PPS) for the treatment of medical conditions and diseases. Paradigm’s share price has tripled...

The biotechnology company is undergoing regulatory processes in Australia, the US and Europe for its injectable Pentosan Polysulfate Sodium (iPPS) drug.